Glucagon Market By Product Type , By Application By Distribution Channel : Global Opportunity Analysis and Industry Forecast, 2024-2033

Description

The glucagon market was valued at $0.3 billion in 2023, and is projected to reach $0.6 billion by 2033, growing at a CAGR of 6.4% from 2024 to 2033.

Glucagon is a peptide hormone produced by the alpha cells of the pancreas. It plays a critical role in glucose metabolism by increasing blood glucose levels when they drop too low, thus maintaining energy balance in the body. This hormone primarily acts on the liver, promoting glycogen breakdown (glycogenolysis) and stimulating the production of glucose from non-carbohydrate sources (gluconeogenesis). Glucagon works in opposition to insulin, which lowers blood glucose levels.

Alarming rise in global incidence of diabetes, particularly Type 1 diabetes, drives the demand for glucagon as it is a critical treatment for managing severe hypoglycemia. The International Diabetes Federation (2023) estimates that over 540 million adults live with diabetes globally, highlighting the importance of glucagon therapy. In addition, educational initiatives by healthcare organizations about hypoglycemia management have increased the adoption of glucagon products, particularly among diabetic patients at high risk for severe hypoglycemic episodes. Moreover, surge in geriatric population acts as the key driving force of the global market. With the aging global population, there is a growing number of individuals at risk for diabetes and related complications, driving the demand for glucagon products. A 2024 study published by the World Health Organization revealed that the number of aged individuals will increase from 1 billion in 2020 to 1.4 billion by 2030. Moreover, the number of individuals aging 80 years and older is estimated to reach 426 million by 2050. Furthermore, beyond its use in hypoglycemia, glucagon is increasingly employed in diagnostic imaging procedures (e.g., radiology and endoscopy) to relax the gastrointestinal tract, broadening its market scope. However, high cost of glucagon therapies, especially for newer formulations such as nasal glucagon, can be a significant barrier to access for patients, particularly in low-income regions or for those without sufficient healthcare coverage. The use of glucagon, especially in emergency settings, typically requires guidance from healthcare professionals for proper administration, which can further limit its use in situations where immediate access to medical help is unavailable. On the contrary, innovations such as prefilled syringes, auto-injectors, and nasal glucagon formulations enhance the ease of administration, making glucagon therapy more accessible and user-friendly for patients and caregivers. Such developments are anticipated to open new avenues for the expansion of the global market during the forecast period.

The global glucagon industry is segmented into type, application, distribution channel, and region. On the basis of type, the market is categorized into injectable glucagon and nasal glucagon. As per application, it is segregated into hypoglycemia and diagnostic aid. Depending on distribution channel, it is fragmented into hospital pharmacies, retail pharmacies, and online pharmacies. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Key Findings

By type, the injectable glucagon segment is expected to dominate the market from 2024 to 2033.

On the basis of application, the hypoglycemia segment is anticipated to exhibit the growth of the global market during the forecast period.

Depending on distribution channel, the hospital pharmacies segment is projected to grow at a notable pace throughout the forecast period.

Region wise, the glucagon market is likely to show strong growth in North America.

Competition Analysis

The major players operating in the global glucagon market include Novo Nordisk A/S, Fresenius SE & Co. KGaA, Amphastar Pharmaceuticals, Inc., Xeris Biopharma Holdings, Inc., ILS Inc, United Biotech (P) Limited, Zealand Pharma A/S, Taj Pharmaceuticals Limited, Eli Lilly and Company, and Pfizer Inc. These major players have adopted various key development strategies such as business expansion, new product launches, and partnerships to sustain the intense competition and gain a strong foothold in the global market.

Additional benefits you will get with this purchase are:

Quarterly Update and* (only available with a corporate license, on listed price)
5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
Free Upcoming Version on the Purchase of Five and Enterprise User License.
16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
Free data Pack on the Five and Enterprise User License. (Excel version of the report)
Free Updated report if the report is 6-12 months old or older.
24-hour priority response*
Free Industry updates and white papers.

Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)

Regulatory Guidelines
Additional company profiles with specific to client's interest
Expanded list for Company Profiles
Reimbursement Scenario

Key Market Segments

By Product Type

Injectable Glucagon
Nasal Glucagon

By Application

Hypoglycemia
Diagnostic Aid

By Distribution Channel

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies

By Region

North America
- U.S.
- Canada
- Mexico
Europe
- France
- Germany
- Italy
- Spain
- UK
- Rest of Europe
Asia-Pacific
- China
- Japan
- India
- South Korea
- Australia
- Rest of Asia-Pacific
LAMEA
- Brazil
- South Africa
- Saudi Arabia
- Rest of LAMEA

Key Market Players:

Novo Nordisk A/S
Fresenius SE & Co. KGaA
Amphastar Pharmaceuticals, Inc.
Xeris Biopharma Holdings, Inc.
ILS Inc
United Biotech (P) Limited
Zealand Pharma A/S
Taj Pharmaceuticals Limited
Eli Lilly and Company.
Pfizer Inc.

Product Code: A324426

CHAPTER 1: INTRODUCTION

1.1. Report Description
1.2. Key Market Segments
1.3. Key Benefits
1.4. Research Methodology
- 1.4.1. Primary Research
- 1.4.2. Secondary Research
- 1.4.3. Analyst Tools and Models

CHAPTER 2: EXECUTIVE SUMMARY

2.1. CXO Perspective

CHAPTER 3: MARKET LANDSCAPE

3.1. Market Definition and Scope
3.2. Key Findings
- 3.2.1. Top Investment Pockets
- 3.2.2. Top Winning Strategies
3.3. Porter's Five Forces Analysis
- 3.3.1. Bargaining Power of Suppliers
- 3.3.2. Threat of New Entrants
- 3.3.3. Threat of Substitutes
- 3.3.4. Competitive Rivalry
- 3.3.5. Bargaining Power among Buyers
3.4. Market Dynamics
- 3.4.1. Drivers
- 3.4.2. Restraints
- 3.4.3. Opportunities

CHAPTER 4: GLUCAGON MARKET, BY PRODUCT TYPE

4.1. Market Overview
- 4.1.1 Market Size and Forecast, By Product Type
4.2. Injectable Glucagon
- 4.2.1. Key Market Trends, Growth Factors and Opportunities
- 4.2.2. Market Size and Forecast, By Region
- 4.2.3. Market Share Analysis, By Country
4.3. Nasal Glucagon
- 4.3.1. Key Market Trends, Growth Factors and Opportunities
- 4.3.2. Market Size and Forecast, By Region
- 4.3.3. Market Share Analysis, By Country

CHAPTER 5: GLUCAGON MARKET, BY APPLICATION

5.1. Market Overview
- 5.1.1 Market Size and Forecast, By Application
5.2. Hypoglycemia
- 5.2.1. Key Market Trends, Growth Factors and Opportunities
- 5.2.2. Market Size and Forecast, By Region
- 5.2.3. Market Share Analysis, By Country
5.3. Diagnostic Aid
- 5.3.1. Key Market Trends, Growth Factors and Opportunities
- 5.3.2. Market Size and Forecast, By Region
- 5.3.3. Market Share Analysis, By Country

CHAPTER 6: GLUCAGON MARKET, BY DISTRIBUTION CHANNEL

6.1. Market Overview
- 6.1.1 Market Size and Forecast, By Distribution Channel
6.2. Hospital Pharmacies
- 6.2.1. Key Market Trends, Growth Factors and Opportunities
- 6.2.2. Market Size and Forecast, By Region
- 6.2.3. Market Share Analysis, By Country
6.3. Retail Pharmacies
- 6.3.1. Key Market Trends, Growth Factors and Opportunities
- 6.3.2. Market Size and Forecast, By Region
- 6.3.3. Market Share Analysis, By Country
6.4. Online Pharmacies
- 6.4.1. Key Market Trends, Growth Factors and Opportunities
- 6.4.2. Market Size and Forecast, By Region
- 6.4.3. Market Share Analysis, By Country

CHAPTER 7: GLUCAGON MARKET, BY REGION

7.1. Market Overview
- 7.1.1 Market Size and Forecast, By Region
7.2. North America
- 7.2.1. Key Market Trends and Opportunities
- 7.2.2. Market Size and Forecast, By Product Type
- 7.2.3. Market Size and Forecast, By Application
- 7.2.4. Market Size and Forecast, By Distribution Channel
- 7.2.5. Market Size and Forecast, By Country
- 7.2.6. U.S. Glucagon Market
  - 7.2.6.1. Market Size and Forecast, By Product Type
  - 7.2.6.2. Market Size and Forecast, By Application
  - 7.2.6.3. Market Size and Forecast, By Distribution Channel
- 7.2.7. Canada Glucagon Market
  - 7.2.7.1. Market Size and Forecast, By Product Type
  - 7.2.7.2. Market Size and Forecast, By Application
  - 7.2.7.3. Market Size and Forecast, By Distribution Channel
- 7.2.8. Mexico Glucagon Market
  - 7.2.8.1. Market Size and Forecast, By Product Type
  - 7.2.8.2. Market Size and Forecast, By Application
  - 7.2.8.3. Market Size and Forecast, By Distribution Channel
7.3. Europe
- 7.3.1. Key Market Trends and Opportunities
- 7.3.2. Market Size and Forecast, By Product Type
- 7.3.3. Market Size and Forecast, By Application
- 7.3.4. Market Size and Forecast, By Distribution Channel
- 7.3.5. Market Size and Forecast, By Country
- 7.3.6. France Glucagon Market
  - 7.3.6.1. Market Size and Forecast, By Product Type
  - 7.3.6.2. Market Size and Forecast, By Application
  - 7.3.6.3. Market Size and Forecast, By Distribution Channel
- 7.3.7. Germany Glucagon Market
  - 7.3.7.1. Market Size and Forecast, By Product Type
  - 7.3.7.2. Market Size and Forecast, By Application
  - 7.3.7.3. Market Size and Forecast, By Distribution Channel
- 7.3.8. Italy Glucagon Market
  - 7.3.8.1. Market Size and Forecast, By Product Type
  - 7.3.8.2. Market Size and Forecast, By Application
  - 7.3.8.3. Market Size and Forecast, By Distribution Channel
- 7.3.9. Spain Glucagon Market
  - 7.3.9.1. Market Size and Forecast, By Product Type
  - 7.3.9.2. Market Size and Forecast, By Application
  - 7.3.9.3. Market Size and Forecast, By Distribution Channel
- 7.3.10. UK Glucagon Market
  - 7.3.10.1. Market Size and Forecast, By Product Type
  - 7.3.10.2. Market Size and Forecast, By Application
  - 7.3.10.3. Market Size and Forecast, By Distribution Channel
- 7.3.11. Rest Of Europe Glucagon Market
  - 7.3.11.1. Market Size and Forecast, By Product Type
  - 7.3.11.2. Market Size and Forecast, By Application
  - 7.3.11.3. Market Size and Forecast, By Distribution Channel
7.4. Asia-Pacific
- 7.4.1. Key Market Trends and Opportunities
- 7.4.2. Market Size and Forecast, By Product Type
- 7.4.3. Market Size and Forecast, By Application
- 7.4.4. Market Size and Forecast, By Distribution Channel
- 7.4.5. Market Size and Forecast, By Country
- 7.4.6. China Glucagon Market
  - 7.4.6.1. Market Size and Forecast, By Product Type
  - 7.4.6.2. Market Size and Forecast, By Application
  - 7.4.6.3. Market Size and Forecast, By Distribution Channel
- 7.4.7. Japan Glucagon Market
  - 7.4.7.1. Market Size and Forecast, By Product Type
  - 7.4.7.2. Market Size and Forecast, By Application
  - 7.4.7.3. Market Size and Forecast, By Distribution Channel
- 7.4.8. India Glucagon Market
  - 7.4.8.1. Market Size and Forecast, By Product Type
  - 7.4.8.2. Market Size and Forecast, By Application
  - 7.4.8.3. Market Size and Forecast, By Distribution Channel
- 7.4.9. South Korea Glucagon Market
  - 7.4.9.1. Market Size and Forecast, By Product Type
  - 7.4.9.2. Market Size and Forecast, By Application
  - 7.4.9.3. Market Size and Forecast, By Distribution Channel
- 7.4.10. Australia Glucagon Market
  - 7.4.10.1. Market Size and Forecast, By Product Type
  - 7.4.10.2. Market Size and Forecast, By Application
  - 7.4.10.3. Market Size and Forecast, By Distribution Channel
- 7.4.11. Rest of Asia-Pacific Glucagon Market
  - 7.4.11.1. Market Size and Forecast, By Product Type
  - 7.4.11.2. Market Size and Forecast, By Application
  - 7.4.11.3. Market Size and Forecast, By Distribution Channel
7.5. LAMEA
- 7.5.1. Key Market Trends and Opportunities
- 7.5.2. Market Size and Forecast, By Product Type
- 7.5.3. Market Size and Forecast, By Application
- 7.5.4. Market Size and Forecast, By Distribution Channel
- 7.5.5. Market Size and Forecast, By Country
- 7.5.6. Brazil Glucagon Market
  - 7.5.6.1. Market Size and Forecast, By Product Type
  - 7.5.6.2. Market Size and Forecast, By Application
  - 7.5.6.3. Market Size and Forecast, By Distribution Channel
- 7.5.7. South Africa Glucagon Market
  - 7.5.7.1. Market Size and Forecast, By Product Type
  - 7.5.7.2. Market Size and Forecast, By Application
  - 7.5.7.3. Market Size and Forecast, By Distribution Channel
- 7.5.8. Saudi Arabia Glucagon Market
  - 7.5.8.1. Market Size and Forecast, By Product Type
  - 7.5.8.2. Market Size and Forecast, By Application
  - 7.5.8.3. Market Size and Forecast, By Distribution Channel
- 7.5.9. Rest of LAMEA Glucagon Market
  - 7.5.9.1. Market Size and Forecast, By Product Type
  - 7.5.9.2. Market Size and Forecast, By Application
  - 7.5.9.3. Market Size and Forecast, By Distribution Channel

CHAPTER 8: COMPETITIVE LANDSCAPE

8.1. Introduction
8.2. Top Winning Strategies
8.3. Product Mapping Of Top 10 Player
8.4. Competitive Dashboard
8.5. Competitive Heatmap
8.6. Top Player Positioning, 2023

CHAPTER 9: COMPANY PROFILES

9.1. Novo Nordisk A/S
- 9.1.1. Company Overview
- 9.1.2. Key Executives
- 9.1.3. Company Snapshot
- 9.1.4. Operating Business Segments
- 9.1.5. Product Portfolio
- 9.1.6. Business Performance
- 9.1.7. Key Strategic Moves and Developments
9.2. Fresenius SE And Co. KGaA
- 9.2.1. Company Overview
- 9.2.2. Key Executives
- 9.2.3. Company Snapshot
- 9.2.4. Operating Business Segments
- 9.2.5. Product Portfolio
- 9.2.6. Business Performance
- 9.2.7. Key Strategic Moves and Developments
9.3. Amphastar Pharmaceuticals, Inc.
- 9.3.1. Company Overview
- 9.3.2. Key Executives
- 9.3.3. Company Snapshot
- 9.3.4. Operating Business Segments
- 9.3.5. Product Portfolio
- 9.3.6. Business Performance
- 9.3.7. Key Strategic Moves and Developments
9.4. Xeris Biopharma Holdings, Inc.
- 9.4.1. Company Overview
- 9.4.2. Key Executives
- 9.4.3. Company Snapshot
- 9.4.4. Operating Business Segments
- 9.4.5. Product Portfolio
- 9.4.6. Business Performance
- 9.4.7. Key Strategic Moves and Developments
9.5. ILS Inc
- 9.5.1. Company Overview
- 9.5.2. Key Executives
- 9.5.3. Company Snapshot
- 9.5.4. Operating Business Segments
- 9.5.5. Product Portfolio
- 9.5.6. Business Performance
- 9.5.7. Key Strategic Moves and Developments
9.6. United Biotech (P) Limited
- 9.6.1. Company Overview
- 9.6.2. Key Executives
- 9.6.3. Company Snapshot
- 9.6.4. Operating Business Segments
- 9.6.5. Product Portfolio
- 9.6.6. Business Performance
- 9.6.7. Key Strategic Moves and Developments
9.7. Zealand Pharma A/S
- 9.7.1. Company Overview
- 9.7.2. Key Executives
- 9.7.3. Company Snapshot
- 9.7.4. Operating Business Segments
- 9.7.5. Product Portfolio
- 9.7.6. Business Performance
- 9.7.7. Key Strategic Moves and Developments
9.8. Taj Pharmaceuticals Limited
- 9.8.1. Company Overview
- 9.8.2. Key Executives
- 9.8.3. Company Snapshot
- 9.8.4. Operating Business Segments
- 9.8.5. Product Portfolio
- 9.8.6. Business Performance
- 9.8.7. Key Strategic Moves and Developments
9.9. Eli Lilly And Company.
- 9.9.1. Company Overview
- 9.9.2. Key Executives
- 9.9.3. Company Snapshot
- 9.9.4. Operating Business Segments
- 9.9.5. Product Portfolio
- 9.9.6. Business Performance
- 9.9.7. Key Strategic Moves and Developments
9.10. Pfizer Inc.
- 9.10.1. Company Overview
- 9.10.2. Key Executives
- 9.10.3. Company Snapshot
- 9.10.4. Operating Business Segments
- 9.10.5. Product Portfolio
- 9.10.6. Business Performance
- 9.10.7. Key Strategic Moves and Developments